Sorrento Therapeutics Inc. is planning to buy Igdrasol, a private company that develops cancer-treatment products.

Fountain Valley, Calif.-based Igdrasol’s products treat metastic breast cancer, non-small lung cancer and other cancers. The company’s Cynviloq product can inject medication into tumors. Cynviloq is approved in South Korea, and has completed Phase 2 testing in the U.S.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.